George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
allis
Nice post - :)
Paraytec -Testing with Photonics.
Just for anyone looking in.
In clinical studies, the Paraytec COVID-19 test has been compared with a qPCR test using a total of 52 clinical nasal swab subject specimens, of which 39 were designated as COVID-19 positive during NHS PCR testing and 13 as COVID-19 negative.. The viral load in each specimen was determined by qPCR and specimens containing a range of viral loads were transferred into Paraytec’s newly developed Viral Transport Medium to test the laboratory performance of Paraytec’s photonics-based test. Using a maximum cycle threshold (Ct) value of 37, Paraytec’s q-PCR testing regime has a sensitivity and specificity of 97.4% and 100% respectively. In the laboratory, the Paraytec test achieved 94% sensitivity and 100% specificity. Importantly, these results correspond to clinical specimens with viral loads of approximately 100,000 virions per millilitre or less.
This outcome is important because it demonstrates the ability of the Paraytec test to identify people with relatively low viral loads – many of whom would be asymptomatic individuals or those with early stage infection. The results demonstrate the potential performance advantage of the Paraytec test over lateral flow tests, which have only shown high levels of sensitivity in clinical specimens with relatively high viral loads (typically, 500,000 virions per millilitre and higher).
WHAT ! LOL
Prof S - Good Man.
SEPSIS - That's the Game Changer - IMO
GL all Gen LTH
Just have a little patience..........still hurting from the cash I've lost,
I'm feeling your frustration........but maybe one day all the pain will stop.
All of our patience is being tested now,no pun intended.
You'd hope by law of averages 1 or 2 out of 50 or so interested parties would eventually get involved hopefully a buy out situation.
Selling now I would be a considerable loss so no choice but to be patient.
allis,
I hope you get your winter holiday. I admit I have higher hopes for November than i would usually allow myself. Over time I have found that my biggest mistakes have been when I have sold too early thinking a share wasn't going to deliver. Being patient doesn't always work though and I found it takes practice on my part.
Skippy ,
Not an obituary and still invested . Sentiment impotant part.for PI's but Ithink a serious partner ,whethr pharma or eectronic ,will want data and lots of it.
Will admit ro a little impatience as I'm 75 and usually winter hol in Asia
All te best and GLA
You sound like you are writing an obituary for the Covid test.
The last RNS stated where the test was and from that it is clear that it is still in play. We are awaiting news. This does not mean I have a crystal ball telling me that it will be a commercial success for BRH but I have zero reasons to change my risk appetite just because it hasn't happened fast enough for those who don't have as much patience as I do.
I don't agree with you that investment relies on data. Sentiment is a huge factor in AIM and it won't take much to move this SP - a lot. Yes data too but not exclusively and many AIM investors make a lot just by selling before an RNS.
But yes at some point it would be good to get some more news. I'm well within expectations today as I had assumed we wouldn't get anything new until November unless someone comes along and buys the IP.
After the remarkable and swift development of vaccines and now anti virals , there has been a noticeable absence of progress in covid testing . PCR are surely much better than nothing and perhaps there are improvements in the pipeline , which will make them more accurate and cheaper .
It was n the hope of a radically better alternative , that I invested in BRH and its collaboration with Prof.Smythe / Sheffield University , Early this cryptic messages and YouTube interviews encoraged small top ups , Sadly TB sold up and trashed the SP , an accidental good cop / bad cop.
TB then buys back and decides better dyi than 50 companies who had expressed interest
Was it a problem with the science , not enough money , problems translating the laboratory in to a mass produced testing unit.
Of course we don't know and as other posters regularly observe , rns tomorrow.
I suspect not , but just as Smythe points to science based on data ,so does investment